



Imaxio strengthens the intellectual property of its vaccines pipeline with two new patents granted in the United States

They offer Imaxio additional cover on the American market for the new generation of its antigen re-engineering technology, and for its influenza vaccine candidate

Lyon, France – 19th May 2016 – Imaxio, a biotech company specialized in immunology, announces today having received from the USPTO (United States Patent and Trademark Office) notices of allowance for two of its latest patent applications.

Submitted in 2012 and 2013, and respectively entitled "*Modified coiled-coil type proteins having improved properties*" and "*Influenza nucleoprotein vaccines*", these two patents offer additional cover on the American market to the new generation of Imaxio's antigen re-engineering technology, as well as to its influenza vaccine candidate.^{1, 2}

They follow Imaxio's patents named "*Multimeric complexes of antigens and an adjuvant*" and "*Mycobacterial vaccines*". Respectively submitted in 2005 and 2009, these initial patents compose the current portfolio of Imaxio and offer an international protection to the first generation of its antigen re-engineering technology, as well as to its tuberculosis vaccine candidate co-developed with the Jenner Institute at Oxford University.^{3, 4}

Thus, the two recent notices significantly strengthen the intellectual property of Imaxio's vaccine pipeline, currently composed of two clinical-stage vaccines indicated in the prevention of tuberculosis and malaria, and of several preclinical-stage candidates, indicated in the prevention of influenza and staphylococcus aureus infection, as well as in the treatment of cancer.

Imaxio's pipeline is based on the IMX313 technology, an antigen re-engineering platform which increases significantly antigens immunogenicity and, therefore, the efficacy of vaccines and immunotherapies within which they are used.

"More than the improvements brought to our vaccine candidates, these two new patents give our IMX313 technology platform a supplementary exclusivity of 7 years", adds Mr. Alexandre Le Vert, Chief Executive Officer. "These applications have been submitted in multiple territories and we expect, following the US, to receive additional notices of allowance soon."

About Imaxio SA

Imaxio is a small biotechnology company focused on immunology, with products ranging from commercial stage to clinical and preclinical R&D stages.

Imaxio commercializes in France a human vaccine indicated for the prevention of an infectious occupational disease, called Spirolept®.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases (tuberculosis, malaria, influenza...) and immunotherapies in oncology.

It is based on the IMX313 technology, an antigen re-engineering platform developed by Imaxio to improve the efficacy of vaccines, which is protected by a strong portfolio of 4 patent families.

Imaxio partners with international renowned research structures, including the Jenner Institute at Oxford University (UK), the German Cancer Research Centre (DKFZ), Inserm (France), CNRS (France) and the Léon Bérard Cancer Centre (Lyon, France). Based in Lyon (France), more than half of the twenty Imaxio employees are dedicated to R&D activities. In 2015, its turnover reached EUR 2 million.
For further information: <http://www.imaxio.com>

For further information, please contact:

Imaxio S.A.
Raphaël METROP
rmetrop@imaxio.com

- 1 - PCT/EP2013/076289
- 2 - PCT/EP2014/055438
- 3 - PCT/EP2006/011446
- 4 - PCT/GB2010/051741